AorTech International PLC – Trading Update
AorTech International plc (AIM: AOR.L), the holding company of a group of medical device businesses focused on the exploitation of the world’s leading long-term implantable biostable polymer (Elast-EonTM),
AorTech International plc (AIM: AOR.L), the holding company of a group of medical device businesses focused on the exploitation of the world’s leading long-term implantable biostable polymer (Elast-EonTM),
AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, today announces its unaudited interim results for the six months ended 30 September 2019.
AorTech International plc (AIM: AOR.L), the licensor of the world’s leading long-term implantable biostable polymer (Elast-EonTM) and developer of medical devices utilising the key properties of Elast-EonTM, is pleased to provide the following update for the six months ended 30 September 2019:
AorTech International plc (AIM: AOR), the biomaterials IP and medical device development company, announces its audited final results for the year ended 31 March 2019.
AorTech International plc (AIM: AOR.L), the licensor of the world’s leading long- term implantable biostable polymer (Elast-EonTM) and developer of medical devices utilising the key properties of Elast-EonTM, is pleased to provide the following trading update ahead of the publication of the Group’s audited final results for the financial year ended 31 March 2019 which are expected to be released in mid-July 2019.
AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, announces a conditional placing, subscription and open offer.